46
total announcements
INDSWFTLAB.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 15 Oct 2026
Market Cap
₹3,215 Cr
P/E (TTM)
55.3
EPS (TTM)
₹6.69
52W Low
₹87.15
52W High
₹424.75
Dividend Yield
0.00%
Beta
0.79
Price / Book
2.2
Debt / Equity
1.5
Revenue (TTM)
₹674 Cr
Gross Margin
57.34%
Operating Margin
13.50%
Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited has informed the Exchange about Disclosures under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011, regarding the acquisition of 14,00,000 (Fourteen Lakh) Equity Shares by Essix Biosciences Limited through the conversion of Fully Convertible Warrants.
Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited has informed the Exchange about the conversion of 14,00,000 (Fourteen Lakh) Fully Convertible Warrants into Equity Shares of face value of ₹10/- each, upon receipt of the balance 75% consideration of ₹147/- (Rupees One Hundred and Forty-Seven only) per Warrant, aggregating to ₹20,58,00,000/- (Rupees Twenty Crore Fifty-Eight Lakh only).
Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited has announced a special window for re-lodgement of transfer requests of physical shares and dematerialisation, in compliance with SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/ I/3750/2026 dated January 30, 2026.
Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited has submitted the Exchange a copy Scrutinizers report of Annual General Meeting held on September 30, 2026, and informed the Exchange regarding voting results.
Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited has received a certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September, 2026, confirming the dematerialization of securities.
Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited has held its 31st Annual General Meeting (AGM) on September 30, 2026, through video conferencing. The meeting was attended by 47 shareholders and the necessary quorum was present. The resolutions were passed with the majority approval through remote e-voting.
Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited has intimated shareholders to furnish PAN, KYC details, and Nomination details as per SEBI Master Circular no. SEBI/HO/MIRSD/POD-1/P/CIR/2024/37 dated May 07, 2024.
Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.
Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited has informed the Exchange about the schedule of an analyst/institutional investor meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited has informed the Exchange about Disclosures under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011, regarding the acquisition of 70,00,000 (Seventy Lakh) Fully Convertible Warrants by Essix Biosciences Limited, a promoter group entity, to be convertible into an equivalent number of Equity Shares of the company.
Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited has informed the Exchange regarding allotment of 70,00,000 Fully Convertible Warrants on Preferential Basis to Essix Biosciences Limited, a promoter and promoter group entity, at an issue price of Rs. 196/- per warrant.
Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited has informed the Exchange about the submission of newspaper publications regarding the Notice of the 31st Annual General Meeting, details of e-voting, dispatch of the Notice of AGM and Annual Report, and the availability of the Annual Report for the financial year 2025-26 on the website of the Company and the Stock Exchanges.
Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 30, 2026. The meeting will consider the audited financial statements for the financial year ended March 31, 2026, and other business.
Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited has informed the Exchange about a copy of newspaper publication.
Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited has announced the outcome of the Preferential Issue Committee meeting, where the committee has taken note of the revised valuation report and made changes to the Explanatory Statement to the Extra-Ordinary General Meeting Notice.
Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited has informed the Exchange regarding Outcome of Board Meeting held on September 02, 2026, where the Board of Directors approved the appointment of Mr. Amit Mathur as Additional Director, reconstitution of the Audit Committee, and other matters.
Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited has responded to the National Stock Exchange's query regarding a sudden spurt in volume, stating that the company has made all necessary disclosures and is not aware of any specific reason for the increase.
Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited has clarified the sudden spurt in volume of its shares, stating that it is not aware of any specific reason and attributing it to market-driven factors.
Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited has observed a significant increase in volume, prompting the Exchange to write to the company for a response.
Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited has informed the Exchange about Transcript of Earning Call held on August 17, 2026, discussing Q1 FY27 un-audited financial results.